RedHill Biopharma (RDHL) announced that the New York Supreme Court has awarded RedHill approximately $1.82M in legal costs and expenses in its action against Kukbo. The award follows, and is in addition to, the New York Supreme Court’s prior summary judgement award of approximately $8.25M in favor of RedHill. 9% ongoing statutory interest accrual is applicable to both the original summary judgment and the award of legal costs and expenses. RedHill also succeeded in its application to Korea’s Incheon District Court for an attachment grant against Kukbo. This provides a court-ordered seizure of Kukbo’s assets, preventing their disposal prior to judgment enforcement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDHL:
- RedHill Biopharma Secures $1.1 Million from Talicia’s First International Sales
- RedHill Biopharma receives Talicia licensing payments totaling $1.1M
- RedHill Biopharma Granted Nasdaq Compliance Extension
- RedHill Biopharma Gains FDA Support for Innovative Crohn’s Disease Therapy
- RedHill Biopharma receives positive FDA feedback for RHB-204 in Crohn’s Disease